Yahoo Finance Plus presents 'Investing in the new high-inflation, slowing-growth paradigm'

Analyst Callie Cox joins Jared Blikre to help investors find opportunities in a tough market on Wed, May 18 at 2pm ET.

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

63.56

+0.38

(+0.59%)

As of 12:05PM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Triple Moving Average Crossover

View all chart patterns

Performance Outlook

Previous Close	63.18
Open	63.14
Bid	63.45 x 800
Ask	63.48 x 1100
Day's Range	62.69 - 63.61
52 Week Range	57.19 - 74.12
Volume	2,784,860
Avg. Volume	9,910,063

Market Cap	79.718B
Beta (5Y Monthly)	0.42
PE Ratio (TTM)	17.75
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	2.92 (4.62%)
Ex-Dividend Date	Jun 14, 2022
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Undervalued

32% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for GILD

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Gilead Sciences, Inc.
Analyst Report: Gilead Sciences, Inc.Gilead Sciences is a California-based biopharmaceutical company that researches, develops, and sells therapies for treating HIV, hepatitis B, hepatitis C, and certain cancers. In October 2020, Gilead's Veklury (remdesivir) became the first approved treatment for COVID-19 in the U.S. Founded in 1987, the company is located in Foster City, California. It has operations in more than 35 countries and approximately 14,400 employees.
Rating
Fair Value
Economic Moat
8 days agoArgus Research

News

Benzinga
Gilead Sciences' Can Resume Injectable Lenacapavir Trial(s) For HIV Infection
The FDA has lifted the clinical hold placed on Gilead Sciences Inc's (NASDAQ: GILD) Investigational New Drug Application to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis. The agency has removed the clinical hold after reviewing Gilead's comprehensive plan and corresponding data on the storage and compatibility of lenacapavir injection with an alternative vial made from aluminosilicate glass. Related: FDA Slaps Clinical Hold On Gilead's Injectable Lenacapavir
Zacks
Gilead (GILD) HIV Studies Removed From FDA's Clinical Hold
Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.
- Gilead Sciences' Can Resume Injectable Lenacapavir Trial(s) For HIV Infection
  Benzinga
- FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV
  Business Wire
American City Business Journals
Stock rebound uncertain for U.S. biotechs as risks multiply for investors
U.S. biotechs and other health care stocks accounted for about 11% of all losses in U.S. equity values during the five-month period analyzed by The Business Journals.